Mutant Molecules of Interest in Myeloproliferative Neoplasms: Introduction | Citedby Results | Acta Haematologica | Karger Publishers

Skip to Main Content

Skip Nav Destination

Mutant Molecules of Interest in Myeloproliferative Neoplasms: Introduction

Acta Haematol (2008) 119 (4): 192–193.

This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.

Austrian recommendations for the management of essential thrombocythemia

Veronika Buxhofer-Ausch
Sonja Heibl
Thamer Sliwa
Christine Beham-Schmid
Dominik Wolf
Klaus Geissler
Maria Theresa Krauth
Peter Krippl
Andreas Petzer
Albert Wölfler
Thomas Melchardt
Heinz Gisslinger

Wiener klinische Wochenschrift (2021) 133 (1-2): 52.

Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5

Sameer Ahamd Guru
Mamta P. Sumi
Rashid Mir
Ajaz Ahmad Waza
Musadiq Ahmad Bhat
Mariyam Zuberi
Promod Lali
Alpana Saxena

Human Cell (2020) 33 (4): 1099.

Acute megakaryoblastic transformation from essential thrombocythemia

Tariq M. Roshan
Ashish B. Rajput
Philip Berardi
Ruth Padmore

Human Pathology: Case Reports (2017) 8: 37.

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk‐stratification, and management

Ayalew Tefferi
Tiziano Barbui

American Journal of Hematology (2017) 92 (1): 94.

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk‐stratification and management

Ayalew Tefferi
Tiziano Barbui

American Journal of Hematology (2015) 90 (2): 162.